← Eichor
Condition: Immunotherapy Esophagus Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Immunotherapy Esophagus Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT04892849Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05624099Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally U
Phase 2 · 1 location(s) · Fuzhou General Hospital · NCT05515315Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT07070466A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophag
Phase 3 · 1 location(s) · Renmin Hospital of Wuhan University · NCT05919030Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NA · 1 location(s) · The Second Hospital of Shandong University · NCT04688801DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07162506Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurg
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07317609SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Phase 3 · 1 location(s) · Ruijin Hospital · NCT06339060Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06569459Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT07001592Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06413342Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · Chuangzhen Chen · NCT07071103Precision Palliative Care for Patients With Advanced Esophageal Cancer
Phase N/A · 1 location(s) · Fudan University · NCT06787313Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06272214MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06498752Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Phase N/A · 1 location(s) · Renmin Hospital of Wuhan University · NCT05894369Neoadjuvant Treatment Modalities in Esophageal Cancer
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT04821843The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)
Phase N/A · 1 location(s) · Second Xiangya Hospital of Central South University · NCT05967910TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06532799Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06429839Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Phase 2 · 8 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT05177133Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squam
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06843889Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Can
Phase N/A · 1 location(s) · Zhao Jun · NCT06790797Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06430658Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06385730
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.